GlassScriptPhysician profile
Jack Ellis Dupee
NPI 1194318600
$4,238.21
in general payments reported to CMS, 2019-2025
22 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $368 · 2023: $922 · 2024: $1,388 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Education: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.61 |
| Education | $381.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,140.61 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $451.50 | 2022-2025 | |
| Genzyme Corporation | $439.91 | 2022-2025 | |
| Ucb, INC. | $378.44 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $310.75 | 2022-2025 | Ilumya |
| Pfizer INC. | $242.48 | 2023-2025 | |
| Galderma Laboratories, L.P. | $181.09 | 2025 | Nemluvio |
| Leo Pharma INC. | $139.05 | 2023-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $136.44 | 2023 | Sotyktu |
| Incyte Corporation | $114.05 | 2023-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Janssen Biotech, INC. | $91.46 | 2023-2025 | Tremfya |
| Amgen INC. | $91.27 | 2025 | Otezla |
| Organon LLC | $85.54 | 2024-2025 | Vtama |
| Dermavant Sciences, INC. | $84.36 | 2024 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72.39 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $61.75 | 2025 | |
| Genentech USA, INC. | $34.83 | 2022 | |
| Arcutis Biotherapeutics, INC. | $29.62 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.36 | 2023 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.46 | 2023 | Jublia |
| Verrica Pharmaceuticals INC. | $14.86 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Dupee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.